
    
      This is a first-time-in-human (FTiH) Phase 1, multicenter, open-label, dose-escalation, and
      dose-expansion study of MEDI0562 to evaluate the safety, tolerability, pharmacokinetics,
      immunogenicity, pharmacodynamics and preliminary anti-tumor activity in adult subjects with
      selected advanced solid tumors.
    
  